Accuray Incorporated (ARAY)

$1.92

+0.05

(+2.67%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.86
    $1.94
    $1.92
    downward going graph

    3.39%

    Downside

    Day's Volatility :4.38%

    Upside

    1.03%

    downward going graph
  • $1.46
    $4.30
    $1.92
    downward going graph

    23.96%

    Downside

    52 Weeks Volatility :66.05%

    Upside

    55.35%

    downward going graph

Returns

PeriodAccuray IncorporatedSector (Health Care)Index (Russel 2000)
3 Months
-14.61%
6.5%
0.0%
6 Months
-32.0%
7.1%
0.0%
1 Year
-52.9%
9.8%
0.0%
3 Years
-54.61%
14.2%
-20.2%

Highlights

Market Capitalization
192.5M
Book Value
$0.41
Earnings Per Share (EPS)
-0.22
PEG Ratio
0.08
Wall Street Target Price
6.0
Profit Margin
-4.99%
Operating Margin TTM
3.73%
Return On Assets TTM
-0.56%
Return On Equity TTM
-44.87%
Revenue TTM
430.6M
Revenue Per Share TTM
4.42
Quarterly Revenue Growth YOY
16.8%
Gross Profit TTM
154.0M
EBITDA
1.3M
Diluted Eps TTM
-0.22
Quarterly Earnings Growth YOY
-0.96
EPS Estimate Current Year
-0.17
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.01
EPS Estimate Next Quarter
0.06

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Accuray Incorporated(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 212.5%

Current $1.92
Target $6.00

Company Financials

FY18Y/Y Change
Revenue
404.9M
↑ 5.6%
Net Income
-23.9M
↓ 19.2%
Net Profit Margin
-5.9%
↑ 1.81%
FY19Y/Y Change
Revenue
418.8M
↑ 3.43%
Net Income
-16.4M
↓ 31.25%
Net Profit Margin
-3.92%
↑ 1.98%
FY20Y/Y Change
Revenue
382.9M
↓ 8.56%
Net Income
3.8M
↓ 123.29%
Net Profit Margin
1.0%
↑ 4.92%
FY21Y/Y Change
Revenue
396.3M
↑ 3.49%
Net Income
-6.3M
↓ 264.91%
Net Profit Margin
-1.59%
↓ 2.59%
FY22Y/Y Change
Revenue
429.9M
↑ 8.48%
Net Income
-5.3M
↓ 15.27%
Net Profit Margin
-1.24%
↑ 0.35%
FY23Y/Y Change
Revenue
447.6M
↑ 4.12%
Net Income
-9.3M
↑ 73.56%
Net Profit Margin
-2.07%
↓ 0.83%
Q4 FY22Q/Q Change
Revenue
114.8M
↑ 18.93%
Net Income
-1.9M
↓ 65.61%
Net Profit Margin
-1.63%
↑ 4.02%
Q1 FY23Q/Q Change
Revenue
118.1M
↑ 2.88%
Net Income
599.0K
↓ 131.96%
Net Profit Margin
0.51%
↑ 2.14%
Q2 FY23Q/Q Change
Revenue
118.3M
↑ 0.2%
Net Income
-2.6M
↓ 526.71%
Net Profit Margin
-2.16%
↓ 2.67%
Q3 FY23Q/Q Change
Revenue
103.9M
↓ 12.17%
Net Income
-3.0M
↑ 16.16%
Net Profit Margin
-2.86%
↓ 0.7%
Q4 FY23Q/Q Change
Revenue
107.2M
↑ 3.22%
Net Income
-9.6M
↑ 224.05%
Net Profit Margin
-8.97%
↓ 6.11%
Q1 FY24Q/Q Change
Revenue
101.1M
↓ 5.69%
Net Income
-6.3M
↓ 34.08%
Net Profit Margin
-6.27%
↑ 2.7%
FY18Y/Y Change
Total Assets
378.7M
↓ 6.82%
Total Liabilities
330.1M
↓ 8.29%
FY19Y/Y Change
Total Assets
438.2M
↑ 15.7%
Total Liabilities
388.3M
↑ 17.64%
FY20Y/Y Change
Total Assets
490.1M
↑ 11.84%
Total Liabilities
427.3M
↑ 10.04%
FY21Y/Y Change
Total Assets
480.1M
↓ 2.04%
Total Liabilities
411.3M
↓ 3.75%
FY22Y/Y Change
Total Assets
472.8M
↓ 1.51%
Total Liabilities
419.7M
↑ 2.04%
FY23Y/Y Change
Total Assets
479.2M
↑ 1.35%
Total Liabilities
425.6M
↑ 1.4%
Q4 FY22Q/Q Change
Total Assets
468.8M
↑ 0.52%
Total Liabilities
417.0M
↓ 0.56%
Q1 FY23Q/Q Change
Total Assets
475.7M
↑ 1.48%
Total Liabilities
421.0M
↑ 0.96%
Q2 FY23Q/Q Change
Total Assets
479.2M
↑ 0.73%
Total Liabilities
425.6M
↑ 1.08%
Q3 FY23Q/Q Change
Total Assets
476.8M
↓ 0.5%
Total Liabilities
425.9M
↑ 0.08%
Q4 FY23Q/Q Change
Total Assets
476.4M
↓ 0.1%
Total Liabilities
428.7M
↑ 0.66%
Q1 FY24Q/Q Change
Total Assets
462.5M
↓ 2.9%
Total Liabilities
421.4M
↓ 1.69%
FY18Y/Y Change
Operating Cash Flow
18.3M
↓ 4923.95%
Investing Cash Flow
17.8M
↓ 0.32%
Financing Cash Flow
-27.5M
↓ 49.66%
FY19Y/Y Change
Operating Cash Flow
-29.6M
↓ 261.7%
Investing Cash Flow
-4.3M
↓ 124.27%
Financing Cash Flow
28.5M
↓ 203.72%
FY20Y/Y Change
Operating Cash Flow
-1.5M
↓ 95.04%
Investing Cash Flow
-3.7M
↓ 13.52%
Financing Cash Flow
26.7M
↓ 6.24%
FY21Y/Y Change
Operating Cash Flow
38.5M
↓ 2721.65%
Investing Cash Flow
-2.4M
↓ 35.65%
Financing Cash Flow
-28.8M
↓ 207.9%
FY22Y/Y Change
Operating Cash Flow
-2.4M
↓ 106.23%
Investing Cash Flow
-4.7M
↑ 96.62%
Financing Cash Flow
-15.4M
↓ 46.64%
FY23Y/Y Change
Operating Cash Flow
15.5M
↓ 747.46%
Investing Cash Flow
-12.7M
↑ 168.84%
Financing Cash Flow
-2.1M
↓ 86.26%
Q4 FY22Q/Q Change
Operating Cash Flow
-18.0M
↓ 39260.87%
Investing Cash Flow
-1.5M
↑ 20.6%
Financing Cash Flow
4.3M
↓ 197.94%
Q1 FY23Q/Q Change
Operating Cash Flow
24.6M
↓ 236.7%
Investing Cash Flow
-1.9M
↑ 23.79%
Financing Cash Flow
-1.5M
↓ 135.09%
Q2 FY23Q/Q Change
Operating Cash Flow
8.9M
↓ 63.94%
Investing Cash Flow
-8.0M
↑ 320.01%
Financing Cash Flow
-522.0K
↓ 65.2%
Q3 FY23Q/Q Change
Operating Cash Flow
-8.6M
↓ 196.73%
Investing Cash Flow
-1.1M
↓ 86.31%
Financing Cash Flow
-1.5M
↑ 187.36%

Technicals Summary

Sell

Neutral

Buy

Accuray Incorporated is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Accuray Incorporated
Accuray Incorporated
4.47%
-32.0%
-52.9%
-54.61%
-54.28%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Accuray Incorporated
Accuray Incorporated
NA
NA
0.08
-0.17
-0.45
-0.01
NA
0.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Accuray Incorporated
Accuray Incorporated
Buy
$192.5M
-54.28%
NA
-4.99%

Insights on Accuray Incorporated

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 107.23M → 101.13M (in $), with an average decrease of 5.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -9.62M → -6.34M (in $), with an average increase of 51.7% per quarter

Institutional Holdings

  • BlackRock Inc

    8.15%

  • Archon Capital Management LLC

    6.56%

  • Neuberger Berman Group LLC

    5.86%

  • Vanguard Group Inc

    5.29%

  • Royce & Associates, LP

    3.30%

  • Heartland Advisors Inc

    2.94%

Company Information

accuray incorporated (nasdaq: aray) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. the company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. for more information, please visit www.accuray.com. for career opportunities, please visit http://www.accuray.com/careers.

Organization
Accuray Incorporated
Employees
1024
CEO
Ms. Suzanne Winter M.B.A.
Industry
Health Technology

Discover More

FAQs